The U.S. Food and Drug Administration has declined to approve an injectable version of Johnson & Johnson's drug Rybrevant for ...

Doctors at Chesapeake Regional Healthcare are able to minimize the pain lung cancer patients undergo with a one-and-done ...

The U.S. Preventive Services Task Force recommends a low-dose CT scan of the chest for anyone who is between ages 50 and 80 ...

“Early detection can reduce lung cancer death rates by 20% — that’s significant,” Dr. Gorbatov says. “In some cases when we ...

Discover the latest advancements in small cell lung cancer through Novotech CRO’s in-depth disease analysis. Gain valuable insights into novel therapies, ongoing clinical trials, and future ...

An NIH modeling study examined the individual and combined effects of cancer prevention, screening, and treatment. A study ...

Teos Therapeutics has potential lung cancer treatment despite issues and strong financial position. Read here to know why we ...

At CURE, we remain steadfastly dedicated to providing our readers with answers about cancer research. At CURE, we remain ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

GSK’s GSK’227 has gained Priority Medicines (PRIME) designation from the EMA for the treatment of relapsed ES-SCLC.

The highly anticipated PROSPECT-Lung trial has officially opened, marking a significant step forward in the quest to improve treatment strategies for patients with resectable non-small cell lung ...

With tumor reduction seen in 48% of the 33 patients studied, the combination treatment had an overall response rate of 21% in ...